Table 1.
Features of DLBCL-NOS patients used for super-SILAC.
Table 2.
Clinical features of the DLBCL-NOS replication cohort.
Fig 1.
Overview of the super-SILAC ratios for the 4 proteins (from high to low fold change), RPL23 (FC 48,4), ARMC6 (FC 10,4), STX4 (FC 6,9), XPNP1 (FC 6,2)) with higher expression in non-GCB and for the 6 proteins (from low to high fold change)(PHPT1 (FC 6,2), PSAP (FC 6,5), PSMG4 (FC 8,2), ADK (FC 10,5), GLMN (FC 15,2), GLB1 (FC 32,9)), with higher expression in GCB DLBCL with on the Y-axis SILAC ratio (FC, fold change).
Fig 2.
Western blot of three differentially expressed proteins in the cell lines used for to generate the super-SILAC protein mix.
ARMC6, RPL23, GLMN, for 8 DLBCL cell lines, from left to right: DoHH2, SU-DHL-4, SC-1, SU-DHL-5, SU-DHL-6, SU-DHL-10, U2932, OCI-LY3.
Fig 3.
Representative images of the immunohistochemical staining results of the four selected proteins in GCB and non-GCB DLBCL.
ARMC6 (non-GCB case), GLMN (GCB case) and RPL23 (non-GCB case) showed cytoplasmic expression and ADK (GCB case) staining in this case was observed only in the nucleus.
Fig 4.
Results of the immunohistochemistry of the 4 selected proteins (RPL23, ARMC6, GLMN and ADK).
A. Results of 10 cases with sufficient material for validation and B. results of the replication cohort of 47 independent DLBCL cases.